Stratification of pancreatic ductal adenocarcinoma: combinatorial genetic, stromal, and immunologic markers

ES Knudsen, P Vail, U Balaji, H Ngo, IW Botros… - Clinical Cancer …, 2017 - AACR
ES Knudsen, P Vail, U Balaji, H Ngo, IW Botros, V Makarov, N Riaz, V Balachandran
Clinical Cancer Research, 2017AACR
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is associated with an
immunosuppressive milieu that supports immune system evasion and disease progression.
Here, we interrogated genetic, stromal, and immunologic features of PDAC to delineate
impact on prognosis and means to more effectively employ immunotherapy. Experimental
Design: A cohort of 109 PDAC cases annotated for overall survival was utilized as a primary
discovery cohort. Gene expression analysis defined immunologic subtypes of PDAC that …
Abstract
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is associated with an immunosuppressive milieu that supports immune system evasion and disease progression. Here, we interrogated genetic, stromal, and immunologic features of PDAC to delineate impact on prognosis and means to more effectively employ immunotherapy.
Experimental Design: A cohort of 109 PDAC cases annotated for overall survival was utilized as a primary discovery cohort. Gene expression analysis defined immunologic subtypes of PDAC that were confirmed in the Cancer Genome Atlas dataset. Stromal and metabolic characteristics of PDAC cases were evaluated by histologic analysis and immunostaining. Enumeration of lymphocytes, as well as staining for CD8, FOXP3, CD68, CD163, PDL1, and CTLA4 characterized immune infiltrate. Neoantigens were determined by analysis of whole-exome sequencing data. Random-forest clustering was employed to define multimarker subtypes, with univariate and multivariate analyses interrogating prognostic significance.
Results: PDAC cases exhibited distinct stromal phenotypes that were associated with prognosis, glycolytic and hypoxic biomarkers, and immune infiltrate composition. Immune infiltrate was diverse among PDAC cases and enrichment for M2 macrophages and select immune checkpoints regulators were specifically associated with survival. Composite analysis with neoantigen burden, immunologic, and stromal features defined novel subtypes of PDAC that could have bearing on sensitivity to immunologic therapy approaches. In addition, a subtype with low levels of neoantigens and minimal lymphocyte infiltrate was associated with improved overall survival.
Conclusions: The mutational burden of PDAC is associated with distinct immunosuppressive mechanisms that are conditioned by the tumor stromal environment. The defined subtypes have significance for utilizing immunotherapy in the treatment of PDAC. Clin Cancer Res; 23(15); 4429–40. ©2017 AACR.
AACR